Acta Medica Medianae
Prote Mateje br. 70
11 000 Beograd, Srbija
Tel.: 011/2670 594, lok. 18
E-mail: Vesna V Radovic@hemofarm.com
Copyright 2008 by Faculty of Medicine, University of Nis
USE OF BETA BLOCKERS IN ACUTE CORONARY SYNDROME IN SERBIA IN THE PERIOD 2000 – 2005
Vesna V Radovic
The approaches in prevention and therapy of acute coronary syndrome (ACS) are different ways of conservative and invasive procedures which have contributed to reduction of mortality of ischemic heart disease (IHD) by 20 %, approximately, in many parts of the world in the recent 20 years. Beta blockers (BB) gave significant contribution to prevention and therapy of ACS, especially their use in ACS and in the first years of secondary prevention of IHD. The aim of the study was the estimation of patients with ACS in Serbia in the period 2000 – 2005, as well as the evaluation of use of BB in ACS and resolving dilemma concerning their prescription.
The data about patients were obtained from the National Register for ACS in Serbia. Lately, there has been a marked increase in the number of coronary units (CU) and patients with ACS. In admission diagnoses, there was the largest number of patients with AMI or 69,7 %, with the highest total mortality of 11,7 %. In addition, higher rates of male patients than female ones, as well as an increase of male patients in the age group of 50-59 years, and increase of female patients in the age group of 70-79 years were reported. It is interesting that the rate of female patients is higher than presented in literature. It is noted that the rate of AMI with ST segment elevation (STEMI) is more frequent than AMI without ST elevation (NSTEMI). STEMI is more frequent in younger patients and male ones. Case-fatality of STEMI patients is significantly higher compared with NSTEMI patients (P<0,000). The percentage of patients with ACS treated with BB is still low and it has not been changed significantly in recent years. Acta Medica Medianae 2008;47(3):28-34.
Key words: beta blockers (BB), acute coronary syndrome (ACS), secondary prevention of ischemic heart disease (IHD)